Lung large cell carcinoma

Summary

Lung large cell carcinoma (MONDO:0003050) is a cancer (an umbrella term covering 7 Mondo subtypes) with 3 cohort genes (3 CIViC-evidence somatic drivers) and 35 clinical trials. Molecularly, NRAS Q61K confers sensitivity to Trametinib in Lung Large Cell Carcinoma (CIViC Level D); 5 further subtype–drug associations are mapped below. Top therapeutic interventions include carboplatin, docetaxel anhydrous, and gefitinib.

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Cohort genes: 3
• Clinical trials: 35
• Precision-medicine evidence (CIViC): 6 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung large cell carcinoma
Mondo ID	MONDO:0003050
EFO	EFO:0003050
DOID	DOID:4556
NCIT	C4450
SNOMED CT	254629004
UMLS	C0345958
MedGen	91060
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	yes

Also known as: anaplastic lung carcinoma · large cell carcinoma of lung · large cell carcinoma of the lung · large cell lung cancer · large cell lung carcinoma · large cell undifferentiated lung carcinoma · LCLC · lung large cell carcinoma

Data availability: 151 cell lines.

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › large cell carcinoma › lung large cell carcinoma

Related subtypes (4): nasopharyngeal type undifferentiated carcinoma, large cell neuroendocrine carcinoma, salivary gland large cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma

Subtypes (7): pulmonary large cell neuroendocrine carcinoma, basaloid large cell lung carcinoma, lung occult large cell carcinoma, large cell carcinoma with rhabdoid phenotype, lung sarcomatoid carcinoma, lymphoepithelioma-like lung carcinoma, large cell lung carcinoma, clear cell variant

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 21 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
ALK	Act	BRCA,HCC,NBL,NSCLC,PROSTATE,SCLC	CIViC #1
NRAS	Act	ALL,AML,ANGS,CHOL,CLLSLL,COAD,COADREAD,GBM,HCC,LGGNOS,LUAD,LUSC,MEL,MGCT,NPC,OVT,PCM,PROSTATE,SKCM,THYM,UCEC,WDTC	CIViC #36
PDGFRA	Act	CSCC,GB,GBM,HGGNOS,LGGNOS,LUSC,PAST	CIViC #38

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ALK	Orphanet:146	Differentiated thyroid carcinoma
ALK	Orphanet:178342	Inflammatory myofibroblastic tumor
ALK	Orphanet:251877	Ganglioneuroblastoma
ALK	Orphanet:251992	Ganglioneuroma
ALK	Orphanet:300895	ALK-positive anaplastic large cell lymphoma
ALK	Orphanet:364043	ALK-positive large B-cell lymphoma
ALK	Orphanet:626	Large/giant congenital melanocytic nevus
ALK	Orphanet:635	Neuroblastoma
NRAS	Orphanet:146	Differentiated thyroid carcinoma
NRAS	Orphanet:2612	Linear nevus sebaceus syndrome
NRAS	Orphanet:268114	RAS-associated autoimmune leukoproliferative disease
NRAS	Orphanet:389	Langerhans cell histiocytosis
NRAS	Orphanet:626	Large/giant congenital melanocytic nevus
NRAS	Orphanet:648	Noonan syndrome
NRAS	Orphanet:86834	Juvenile myelomonocytic leukemia
PDGFRA	Orphanet:168940	Chronic eosinophilic leukemia
PDGFRA	Orphanet:168947	Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement
PDGFRA	Orphanet:199306	Cleft lip/palate
PDGFRA	Orphanet:314950	Primary hypereosinophilic syndrome
PDGFRA	Orphanet:44890	Gastrointestinal stromal tumor
PDGFRA	Orphanet:585877	B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ALK	HGNC:427	ENSG00000171094	Q9UM73	ALK tyrosine kinase receptor	civic_evidence
NRAS	HGNC:7989	ENSG00000213281	P01111	GTPase NRas	civic_evidence
PDGFRA	HGNC:8803	ENSG00000134853	P16234	Platelet-derived growth factor receptor alpha	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ALK	ALK tyrosine kinase receptor	Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.
NRAS	GTPase NRas	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
PDGFRA	Platelet-derived growth factor receptor alpha	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	2	18.5×	0.008
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ALK	Kinase	yes	2.7.10.1	Prot_kinase_dom, MAM_dom, Ser-Thr/Tyr_kinase_cat_dom
NRAS	Other/Unknown	no		Small_GTPase, Small_GTP-bd, Small_GTPase_Ras-type
PDGFRA	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ cell	1
male germ line stem cell (sensu Vertebrata) in testis	1
sperm	1
epithelium of nasopharynx	1
gingival epithelium	1
secondary oocyte	1
decidua	1
synovial joint	1
tibia	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ALK	181	broad	marker	sperm, male germ cell, male germ line stem cell (sensu Vertebrata) in testis
NRAS	278	ubiquitous	marker	gingival epithelium, epithelium of nasopharynx, secondary oocyte
PDGFRA	289	ubiquitous	marker	tibia, decidua, synovial joint

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NRAS	7,598
PDGFRA	5,186
ALK	4,792

Intra-cohort edges

A	B	Sources
ALK	NRAS	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ALK	Q9UM73	79
NRAS	P01111	35
PDGFRA	P16234	15

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 94. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	2	585.6×	2e-04	NRAS, PDGFRA
Signaling by PDGFRA extracellular domain mutants	2	585.6×	2e-04	NRAS, PDGFRA
Downstream signal transduction	2	253.8×	6e-04	NRAS, PDGFRA
Imatinib-resistant PDGFR mutants	1	3806.7×	0.002	PDGFRA
Sunitinib-resistant PDGFR mutants	1	3806.7×	0.002	PDGFRA
Regorafenib-resistant PDGFR mutants	1	3806.7×	0.002	PDGFRA
Sorafenib-resistant PDGFR mutants	1	3806.7×	0.002	PDGFRA
PDGFR mutants bind TKIs	1	3806.7×	0.002	PDGFRA
Drug resistance of ALK mutants	1	3806.7×	0.002	ALK
ASP-3026-resistant ALK mutants	1	3806.7×	0.002	ALK
NVP-TAE684-resistant ALK mutants	1	3806.7×	0.002	ALK
alectinib-resistant ALK mutants	1	3806.7×	0.002	ALK
brigatinib-resistant ALK mutants	1	3806.7×	0.002	ALK
ceritinib-resistant ALK mutants	1	3806.7×	0.002	ALK
crizotinib-resistant ALK mutants	1	3806.7×	0.002	ALK
lorlatinib-resistant ALK mutants	1	3806.7×	0.002	ALK
Signaling by RAS GAP mutants	1	1268.9×	0.004	NRAS
Signaling by RAS GTPase mutants	1	1268.9×	0.004	NRAS
RAF/MAP kinase cascade	2	40.7×	0.004	NRAS, PDGFRA
MDK and PTN in ALK signaling	1	951.7×	0.005	ALK
Activation of RAS in B cells	1	761.3×	0.006	NRAS
RAS signaling downstream of NF1 loss-of-function variants	1	543.8×	0.008	NRAS
Estrogen-stimulated signaling through PRKCZ	1	543.8×	0.008	NRAS
SOS-mediated signalling	1	475.8×	0.008	NRAS
Activated NTRK3 signals through RAS	1	423.0×	0.009	NRAS
EGFR Transactivation by Gastrin	1	380.7×	0.009	NRAS
SHC-related events triggered by IGF1R	1	380.7×	0.009	NRAS
Activated NTRK2 signals through RAS	1	380.7×	0.009	NRAS
MET activates RAS signaling	1	346.1×	0.009	NRAS
Signaling by FGFR4 in disease	1	317.2×	0.009	NRAS

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cell surface receptor protein tyrosine kinase signaling pathway	2	115.8×	0.004	ALK, PDGFRA
protein autophosphorylation	2	96.8×	0.004	ALK, PDGFRA
platelet-derived growth factor receptor-alpha signaling pathway	1	2808.7×	0.006	PDGFRA
response to environmental enrichment	1	2808.7×	0.006	ALK
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	1	1872.4×	0.006	PDGFRA
metanephric glomerular capillary formation	1	1872.4×	0.006	PDGFRA
regulation of dopamine receptor signaling pathway	1	1404.3×	0.006	ALK
regulation of mesenchymal stem cell differentiation	1	1404.3×	0.006	PDGFRA
swimming behavior	1	1123.5×	0.006	ALK
response to stress	1	802.5×	0.007	ALK
luteinization	1	624.1×	0.007	PDGFRA
negative regulation of platelet activation	1	624.1×	0.007	PDGFRA
peptidyl-tyrosine autophosphorylation	1	624.1×	0.007	ALK
cell activation	1	561.7×	0.007	PDGFRA
retina vasculature development in camera-type eye	1	561.7×	0.007	PDGFRA
phosphorylation	1	432.1×	0.009	ALK
cardiac myofibril assembly	1	432.1×	0.009	PDGFRA
Leydig cell differentiation	1	401.2×	0.009	PDGFRA
positive regulation of dendrite development	1	330.4×	0.009	ALK
embryonic digestive tract morphogenesis	1	312.1×	0.009	PDGFRA
male genitalia development	1	295.6×	0.009	PDGFRA
white fat cell differentiation	1	280.9×	0.009	PDGFRA
positive regulation of chemotaxis	1	280.9×	0.009	PDGFRA
negative regulation of lipid catabolic process	1	280.9×	0.009	ALK
regulation of neuron differentiation	1	244.2×	0.010	ALK
signal transduction involved in regulation of gene expression	1	234.1×	0.010	PDGFRA
adrenal gland development	1	224.7×	0.010	PDGFRA
estrogen metabolic process	1	208.1×	0.011	PDGFRA
embryonic cranial skeleton morphogenesis	1	193.7×	0.011	PDGFRA
platelet-derived growth factor receptor signaling pathway	1	187.2×	0.011	PDGFRA

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carboplatin	Phase 3 (in late-stage trials)
Erlotinib	Phase 3 (in late-stage trials)
Figitumumab	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab, Cisplatin, Durvalumab, Etoposide, Filgrastim, Gemcitabine, Metformin, Nivolumab, Pegfilgrastim, Pemetrexed, Vinorelbine.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 0

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ALK	CERITINIB
PDGFRA	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PDGFRA	77	4
ALK	61	4
NRAS	1	1

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CERITINIB	4	ALK, PDGFRA
BOSUTINIB	4	ALK, PDGFRA
CRIZOTINIB	4	ALK
ALECTINIB	4	ALK
ENTRECTINIB	4	ALK
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK, PDGFRA
RUXOLITINIB	4	ALK
INFIGRATINIB PHOSPHATE	4	ALK, PDGFRA
INFIGRATINIB	4	ALK, PDGFRA
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK, PDGFRA
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK, PDGFRA
NINTEDANIB	4	ALK, PDGFRA
SUNITINIB	4	ALK, PDGFRA
ERLOTINIB	4	ALK, PDGFRA
MIDOSTAURIN	4	ALK, PDGFRA
PONATINIB	4	PDGFRA
TIVOZANIB	4	PDGFRA
LENVATINIB	4	PDGFRA
AXITINIB	4	PDGFRA
SORAFENIB	4	PDGFRA
IMATINIB MESYLATE	4	PDGFRA
REGORAFENIB	4	PDGFRA
NILOTINIB	4	PDGFRA

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ALK	1,815	Binding:1801, Functional:13, ADMET:1
PDGFRA	1,172	Binding:1160, Functional:8, ADMET:4
NRAS	18	Binding:18

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ALK	2.7.10.1	receptor protein-tyrosine kinase
PDGFRA	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ALK	1,815
PDGFRA	1,172

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
CERITINIB	4	ALK, PDGFRA
BOSUTINIB	4	ALK, PDGFRA
ALECTINIB	4	ALK
ENTRECTINIB	4	ALK
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK, PDGFRA
RUXOLITINIB	4	ALK
INFIGRATINIB PHOSPHATE	4	ALK, PDGFRA
INFIGRATINIB	4	ALK, PDGFRA
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK, PDGFRA
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK, PDGFRA
NINTEDANIB	4	ALK, PDGFRA
SUNITINIB	4	ALK, PDGFRA
ERLOTINIB	4	ALK, PDGFRA
MIDOSTAURIN	4	ALK, PDGFRA
PONATINIB	4	PDGFRA
TIVOZANIB	4	PDGFRA
LENVATINIB	4	PDGFRA
AXITINIB	4	PDGFRA
SORAFENIB	4	PDGFRA
IMATINIB MESYLATE	4	PDGFRA
REGORAFENIB	4	PDGFRA
NILOTINIB	4	PDGFRA

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	ALK, PDGFRA
B	Phased (≥1) drug, not yet approved	1	NRAS
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 35.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	17
PHASE1	6
PHASE3	5
PHASE1/PHASE2	3
Not specified	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002852	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
NCT00005838	PHASE3	COMPLETED	Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00020709	PHASE3	COMPLETED	Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00021060	PHASE2/PHASE3	COMPLETED	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00049543	PHASE3	COMPLETED	Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
NCT00946712	PHASE3	TERMINATED	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00334815	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01386385	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03110978	PHASE2	ACTIVE_NOT_RECRUITING	Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
NCT05198830	PHASE2	RECRUITING	Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
NCT00040794	PHASE2	COMPLETED	Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00087412	PHASE2	COMPLETED	S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
NCT00118183	PHASE2	COMPLETED	Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00368992	PHASE2	COMPLETED	S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00950365	PHASE2	COMPLETED	Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
NCT00955305	PHASE2	TERMINATED	Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT01294306	PHASE2	COMPLETED	MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
NCT01557959	PHASE2	COMPLETED	Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01642251	PHASE1/PHASE2	COMPLETED	Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT02134912	PHASE2	TERMINATED	S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
NCT02186847	PHASE2	COMPLETED	Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT02264210	PHASE2	COMPLETED	Icotinib for Completed Resected IB NSCLC With EGFR Mutation
NCT03044626	PHASE2	COMPLETED	Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
NCT03345810	PHASE2	COMPLETED	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
NCT03845296	PHASE2	COMPLETED	Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05566223	PHASE1/PHASE2	WITHDRAWN	CISH Inactivated TILs in the Treatment of NSCLC
NCT00042835	PHASE1	TERMINATED	Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
NCT00369551	PHASE1	TERMINATED	Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT01668823	PHASE1	COMPLETED	Photodynamic Therapy in Treating Patients With Lung Cancer
NCT01958372	PHASE1	COMPLETED	Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
NCT02059967	PHASE1	WITHDRAWN	Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
NCT02535325	PHASE1	COMPLETED	Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
NCT01345851	Not specified	ACTIVE_NOT_RECRUITING	Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT06996249	Not specified	RECRUITING	Prospective Data Collection Initiative on Thoracic Malignancies
NCT03305133	Not specified	COMPLETED	Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	14
DOCETAXEL ANHYDROUS	4	3
GEFITINIB	4	3
PACLITAXEL	4	3
BEVACIZUMAB	4	1
CETUXIMAB	4	1
CRIZOTINIB	4	1
ERLOTINIB HYDROCHLORIDE	4	1
ETOPOSIDE	4	1
PEGFILGRASTIM	4	1
RUCAPARIB	4	1
VINORELBINE	4	1
VELIPARIB	3	4
ICOTINIB	3	1
METHOXYAMINE	2	4
CIXUTUMUMAB	2	1
HPPH	2	1
SOY ISOFLAVONES	2	1
CHEMBL48	0	3
CHEMBL1510899	0	1
CHEMBL1825138	0	1
CHEMBL1825141	0	1
S-ROLIPRAM	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 6 predictive associations from 6 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
NRAS Q61K	Trametinib	Sensitivity/Response	CIViC D	EID12456
PDGFRA Amplification	Trametinib	Sensitivity/Response	CIViC D	EID12457
ALK F1174L	Crizotinib	Resistance	CIViC D	EID4041
ALK R1192P	Crizotinib	Resistance	CIViC D	EID4795
ALK T1151M	Crizotinib	Resistance	CIViC D	EID4431
EML4::ALK Fusion AND ALK I1171S	Crizotinib	Resistance	CIViC D	EID4794